Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II CED of nimustine for brainstem gliomas
jRCT2021190003Phase 2Active, not recruiting
- Start
- May 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nimustine in diffuse intrinsic pontine glioma (DIPG) and brainstem glioma (2 arms). Primary endpoint: 1-year survival rate of pediatric DIPG cases. Started May 2018; status: active, not recruiting.
02
Drugs
nimustine
03
Conditions
diffuse intrinsic pontine glioma (DIPG)brainstem glioma
Beyond the preview
Go deeper on jRCT2021190003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021190003.